Journal
EBIOMEDICINE
Volume 32, Issue -, Pages 119-124Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2018.05.019
Keywords
Anti-CTLA-4; TP53; Melanoma; Biomarker; Tumor mutational
Funding
- National Natural Science Foundation of China [81773285]
Ask authors/readers for more resources
TP53 has been proved to be associatedwith cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastatic melanoma by analyzing the data from one public cohort consisting of 110 patients with metastatic melanoma. The sequencing, mRNA and survival data of 368 patients with skin melanoma from The Cancer Genome Atlas (TCGA) was used to explore the underlying mechanism. TP53 mutation was associated with significant poorer progression-free survival (HR, 2.25; 95% CI, 1.15-4.37; P = 0.014), poorer overall survival (HR, 2.05; 95% CI, 1.02-4.13; P = 0.040) and trend of poorer response (OR, 0.20; 95% CI, 0.02-1.62; P = 0.131). The correlations were significant in multivariate analysis including lactate dehydrogenase, tumor mutational burden and tumor stage (P < 0.05). In TCGA, no association was observed between TP53 mutation and survival (P = 0.55). The mRNA expression of FAS was lower in patientswith TP53 mutation than TP53wild-type. Our findings suggest that TP53mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade. (C) 2018 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available